Bio-Rad Laboratories (NYSE:BIO - Get Free Report) is scheduled to post its quarterly earnings results after the market closes on Wednesday, October 30th. Analysts expect Bio-Rad Laboratories to post earnings of $1.71 per share for the quarter. Bio-Rad Laboratories has set its FY 2024 guidance at EPS.Persons interested in participating in the company's earnings conference call can do so using this link.
Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its earnings results on Thursday, August 1st. The medical research company reported $3.11 earnings per share for the quarter, topping analysts' consensus estimates of $2.12 by $0.99. Bio-Rad Laboratories had a negative net margin of 51.73% and a positive return on equity of 3.77%. The firm had revenue of $638.50 million for the quarter, compared to the consensus estimate of $645.79 million. During the same period in the previous year, the firm posted $3.00 EPS. The business's quarterly revenue was down 6.3% on a year-over-year basis. On average, analysts expect Bio-Rad Laboratories to post $9 EPS for the current fiscal year and $11 EPS for the next fiscal year.
Bio-Rad Laboratories Trading Down 1.4 %
Shares of NYSE:BIO traded down $4.63 during trading on Wednesday, reaching $335.21. The company's stock had a trading volume of 164,427 shares, compared to its average volume of 249,321. The firm's 50 day simple moving average is $331.15 and its two-hundred day simple moving average is $307.25. The company has a current ratio of 6.28, a quick ratio of 4.63 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories has a 12 month low of $261.59 and a 12 month high of $364.24. The stock has a market capitalization of $9.56 billion, a PE ratio of -32.36 and a beta of 0.95.
Insider Buying and Selling
In other Bio-Rad Laboratories news, COO Andrew J. Last sold 3,000 shares of the company's stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $329.94, for a total value of $989,820.00. Following the transaction, the chief operating officer now directly owns 7,559 shares in the company, valued at $2,494,016.46. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, EVP James Barry sold 623 shares of Bio-Rad Laboratories stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total value of $205,895.27. Following the completion of the sale, the executive vice president now directly owns 147 shares in the company, valued at $48,582.03. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, COO Andrew J. Last sold 3,000 shares of the company's stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $329.94, for a total transaction of $989,820.00. Following the completion of the sale, the chief operating officer now directly owns 7,559 shares of the company's stock, valued at approximately $2,494,016.46. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 17.06% of the stock is currently owned by insiders.
Wall Street Analyst Weigh In
A number of brokerages have recently commented on BIO. Wells Fargo & Company began coverage on Bio-Rad Laboratories in a report on Tuesday, August 27th. They issued an "equal weight" rating and a $340.00 target price for the company. Citigroup upgraded shares of Bio-Rad Laboratories from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $350.00 to $400.00 in a research report on Tuesday, October 1st. StockNews.com lowered shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Thursday, August 1st. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $401.00 price objective on shares of Bio-Rad Laboratories in a research note on Friday, August 16th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $368.20.
Get Our Latest Stock Report on Bio-Rad Laboratories
Bio-Rad Laboratories Company Profile
(
Get Free Report)
Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.
Featured Articles
Before you consider Bio-Rad Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Rad Laboratories wasn't on the list.
While Bio-Rad Laboratories currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
